Flumazenil

CNS Drug Reviews

Volumn 2, Issue 4, 1996, Pages 390-414

  Bentue Ferrer D ^a   Bureau, M ^b   Patat, A ^c   Allain, H ^a,d  

^a Inst de Rech Contre le Cancer IRCC   (France)

^b Institute de Chimie de'Rennes   (France)

^c Biotrial SA   (France)

^d Faculté de Médecine   (France)

Author keywords

Anesthesiology; Benzodiazepines; Flumazenil; GABA receptors; Poisoning

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; FLUMAZENIL; FLUNITRAZEPAM; FLURAZEPAM; MECLONAZEPAM; TRIAZOLAM;

ALCOHOLISM; ANTICONVULSANT ACTIVITY; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG ANALYSIS; DRUG ANTAGONISM; DRUG DEPENDENCE; DRUG METABOLISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; EPILEPSY; HEPATIC ENCEPHALOPATHY; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PANIC; SEDATION; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; WITHDRAWAL SYNDROME;

EID: 0030427106     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1996.tb00308.x     Document Type: Article

References (154)

1. Amrein R, Leishman B, Benzinger C, Roncari G. Flumazenil in benzodiazepine antagonism: Actions and clinical use in intoxications and anaesthesiology. Med Toxicol 1987;2:411-429.
2. ® (flumazenil). Acta Anaesthesiol Scand (suppl 92) 1990;34:6-15.
3. Bansky G, Meier PJ, Ziegler WH, Wasler H, Schmid M. Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-1788). Lancet 1985;i:1324-1325.
4. Bansky G, Meier PJ, Rieder E, Wasler H, Ziegler WH. Effects of benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenlerology 1989;97:744-750.
5. Basile AS, Harrison PM, Hughes RD, et al. Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology 1994;19:112-121.
6. A-benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure. Gastroenterology 1987;93:1069-1077.
7. Bernik MA, Gorenstein C, Gentil V. Flumazenil precipitated withdrawal symptoms in chronic users of therapeutic doses of diazepam. J Psychopharmacol 1992;5:215-219.
8. Bertenstein P, Koepp M. Benzodiazepine receptor imaging with positron emission tomography and single photon emission tomography. Nervenarztt 1995;66:412-421.
9. Bhattacharya SK, Glover V, Sandler M, et al. Raised endogenous monoamine oxidase inhibitor output in post withdrawal alcoholics: Effects of L-dopa and ethanol. Biol Psychiatry 1982;17:687-694.
10. Bodenham AR. Death after flumazenil. Br Med J 1989;299:457.
11. Bonetti EP, Pieri L, Cumin R, et al. Benzodiazepine antagonist Ro 15-1788: Neurological and behavioral effects. Psychopharmacology 1982;78:8-18.
12. C receptors. Trends Neurosci 1995;18:415-518.
13. Braestrup C, Honore T, Nielsen M, Petersen EN, Jensen LH. Ligands for benzodiazepine receptors with positive and negative efficacy. Biochem Pharmacol 1984;33:859-862.
14. Breimer LTM, Hennis PJ, Burm AGL, et al. Pharmacokinetics and EEG effects of flumazenil in volunteers. Clin Pharmacokinet 1991;20:491-496.
15. Brogden RN, Goa KL. Flumazenil: A preliminary review of its benzodiazepine antagonist properties, intrinsic activity, and therapeutic use. Drugs 1988;35:448-467.
16. Brogden RN, Goa KL. Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist. Drugs 1991;42:1061-1089.
17. Buck KJ, Heim H, Harris RA. Reversal of alcohol dependence and tolerance by a single administration of flumazenil. J Pharmacol Exp Ther 1991;257:984-989.
18. Bureau M, Olsen RW. GABA/benzodiazepine receptor protein carries binding sites for both ligands on both two major peptide subunits. Biochem Biophys Commun 1988;153:1002-1011.
19. Bureau M, Olsen RW. Multiple distinct subunits of the gamma-aminobutyric acid - A receptor protein show different ligand binding affinities. Mol Pharmacol 1990;37:497-502.
20. A receptor subtypes: Ligand binding heterogeneity demonstrated by photoaffinity labeling and autoradiography. J Neurochem 1993;61:1479-1491.
21. Bureau M, Laschet J, Schoffeniels E. Biochimie comparée des trois cerveaux. Acta Psychiat Belg 1994;94:225-247.
22. Bureau MH, Laschet JJ. Endogenous phosphorylation of distinct γ-aminobutyric acid type A receptor polypeptides by Ser/Thr and Tyr kinase activities associated with the purified receptor. J Biol Chem 1995;270:26482-26487.
23. A chloride channels and benzodiazepine binding sites in baculovirus infected insect cells. BioTechnology 1992;10:679-681.
24. Chan AWK, Leong FW, Schanley DL, Langan MC, Penetrante F. Flumazenil (Ro 15-1788) does not affect ethanol tolerance and dependence. Pharmacol Biochem Behav 1991;39:659-663.
25. Chiolero RL, Ravussin P, Anderes JP, et al. The effect of midazolam reversal by Ro 15-1788 on cerebral perfusion in patients with severe head injury. Intensive Care Med 1989;14:196-200.
26. Clausen TG, Wolff J, Carl P, Theilgaard A. The effect of the benzodiazepine antagonist, flumazenil, on psychometric performance in acute ethanol intoxication in man. Eur J Clin Pharmacol 1990;38:233-236.
27. Clow A, Glover V, Armando I, Sandler M. New endogenous benzodiazepine receptor ligand in human urine: Identity with endogenous monoamine oxidase inhibitor? Life Sci 1983;33:735-741.
28. Clow A, Glover V, Weg MW, et al. Urinary catecholamine metabolite and tribulin output during lactate infusion. Br J Psychiatry 1988;152:122-126.
29. Clow A, Glover V, Sandler M, Tiller J. Increased urinary tribulin output in generalized anxiety disorder. Psychopharmacology 1988;95:378-380.
30. Corda MG, Costa E, Guidotti A. Specific proconvulsant action of an imidazobenzodiazepine (Ro 15-1788) on isoniazid convulsions. Neuropharmacology 1982;21:91-94.
31. Crawley JN, Skolnick P, Paul SM. Absence of intrinsic antagonist actions of benzodiazepine antagonists on an exploratory model of anxiety in the mouse. Neuropharmacology 1984;23:531-537.
32. Curran HV, Birch B. Differentiating the sedative, psychomotor and amnesic effects of benzodiazepines: A study with midazolam and the benzodiazepine antagonist, flumazenil. Psychopharmacology 1991;103:519-523.
33. Da Cunha C, Wolfman C, Levi de Stein M, Ruschel AC, Izquierdo I, Medina JH. Anxiogenic effects of the intra-amygdala injection of flumazenil, a benzodiazepine receptor antagonist. Fund Neurol 1992;7:401-405.
34. Davidson J, Glover V, Clow A, Kudler H, Meador K. Tribulin in post-traumatic stress disorder. Psychol Med 1988;4:833-836.
35. 11C] Ro 15-1788 (flumazenil) in baboon and human during positron emission tomography studies. Eur J Drug Metab Pharmacokinet 1991;16:141-152.
36. Derlet RW, Albertson TE. Flumazenil induces seizures and death in mixed cocaine-diazepam intoxications. Ann Emerg Med 1994;23:494-498.
37. Dodgson MS, Skeie B, Emhjellen S, Wickstrom E, Steen PA. Antagonism of diazepam-induced sedative effects by Ro 15-1788 in patients after surgery under lumbar epidural block. A double-blind placebo-controlled investigation of efficacy and safety. Acta Anesthesiol Scand 1987;31:629-633.
38. 2+. Neuron 1990;5:781-788.
39. Drugan RC, Morrow AL, Weizman R, et al. Stress induced behavioral depression in the rat is associated with a decrease in GABA receptor-mediated chloride ion flux and brain benzodiazepine receptor occupancy. Brain Res 1989;487:45-51.
40. Ferenci P, Schäfer DF, Kleinberger G, Hoofnagke JH, Jones EA. Serum levels of GABA like activity in acute and chronic hepatocellular disease. Lancet 1983;ii:811-814.
41. File SE, Lister RG, Nutt DJ. The anxiogenic action of benzodiazepine antagonists. Neuropharmacology 1982;21:1033-1037.
42. File SE, Pellow S. Intrinsic actions of the benzodiazepine receptor antagonist Ro 15-1788. Psychopharmacology 1986;88:1-11.
43. File SE, Hitchcott PK. A theory of benzodiazepine dependence that can explain whether flumazenil will enhance or reverse the phenomena. Psychopharmacology 1990;101:525-532.
44. Fiset P, Lemmens HLM, Egan TE, Shafer SL, Stanski DR. Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. Clin Pharmacol Ther 1995;58:567-582.
45. Forster A, Crettenand G, Klopfenstein CE, Morel DR. Absence of agonist effects of high dose flumazenil on ventilation and psychometric performance in human volunteers. Anesth Analg 1993;77:980-984.
46. A-benzodiazepine receptor complex purified from the brain of young rats. FEBS Lett 1990;261:52-54.
47. Gallager DW, Heninger K, Heninger G. Periodic benzodiazepine antagonist administration prevents benzodiazepine withdrawal symptoms in primates. Eur J Pharmacol 1986;132:31-38.
48. Galletly DC, Ure R, Turley A. Flumazenil: A twelve month survey of use in a New-Zealand public hospital. Anaesth Int Care 1990;18:229-233.
49. Gammal SH, Basile AS, Geller D, Skolnick P, Jones EA. Reversal of the behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands. Hepalology 1990;11:371-378.
50. Gardner CR, Tully WR, Hedgecock CJR. The rapidly expending range of neuronal benzodiazepine receptor ligands. Prog Neurobiol 1993;40:1-61.
51. Ghoneim MM, Block RI, Ping ST, El-Zahabi MM, Hinrich JV. The interaction of midazolam and flumazenil on human memory and cognition. Anesthesiology 1993;79:1183-1192.
52. Gonsalves SF, Gallager DW. Spontaneous and Ro 15-1788 induced subsensitivity to GABA following chronic benzodiazepine. Eur J Pharmacol 1985;110:163-170.
53. Greene SA, Moore MP, Keegan RD, Gallagher LV. Quantitative electroencephalography for measurement of central nervous system responses to diazepam and the benzodiazepine antagonist, flumazenil, in isoflurane-anaesthetized dogs. J Vet Pharmacol Therap 1992;15:259-266.
54. Griffiths RR, Evans SM, Guarino JJ, et al. Intravenous flumazenil following acute and repeated exposure to lorazepam in healthy volunteers: antagonism and precipitated withdrawal. J Pharmacol Exp Ther 1993;265:1162-1174.
55. Grimm G, Katzenschlager R, Holzner P, et al. Effect of flumazenil in hepatic encephalopathy. Eur J Anaesthesiol (suppl 2) 1988;147-149.
56. Gross JB, Weller RS, Conard P. Flumazenil antagonism of midazolam-induced ventilatory depression. Anesthesiology 1991;75:179-181.
57. Gyr K, Meier R. Flumazenil in the treatment of portal systemic encephalopathy - an overview. Intensive Care Med (suppl 1) 1991;17: S39-S42.
58. Hadingham KL, Wingrove PB, Wafford KA, et al. Role of the β subunit in determining the pharmacology of human gamma aminobutyric acid type A receptors. Mol Pharmacol 1993;44:1211-1218.
59. Hart YM, Meinardi H, Sander JW, Nutt DJ, Shorvon SD. The effect of intravenous flumazenil on interictal electroencephalographic epileptic activity: Results of a placebo-controlled study. J Neurol Neurosurg Psychiatry 1991;54:305-309.
60. Herb A, Wisden W, Lüddens H, Puia G, Vicini S, Seeburg PH. The third gamma subunit of the gamma aminobutyric acid type A receptor family. Proc Natl Acad Sci USA 1992;89:1433-1437.
61. Hichcott PK, File SE, Litlle HJ, Nutt DJ. Diazepam withdrawal: Decreased seizure threshold and increased anxiety reversed by FG 7142 and flumazenil. Soc Neurosci Abstract 1989;15:414.
62. Hoffman EJ, Warren EW. Flumazenil: A benzodiazepine antagonist. Clin Pharm 1993:12:641-656.
63. Hunkeler W, Möhler H, Pieri L, et al. Selective antagonists of benzodiazepines. Nature 1981;290:514-516.
64. Huganir RL, Greengard P. Regulation of neurotransmitter receptor desensitization by protein phosphorylation. Neuron 1990;5:555-567.
65. Imperato A, Dazzi L, Obinu MC, Cessa GL, Biggio G. The benzodiazepine receptor antagonist flumazenil increases acetylcholine release in rat hippocampus. Brain Res 1994;647:167-171.
66. Izquierdo I, Medina JH. GABA receptor modulation of memory: The role of endogenous benzodiazepines. Trends Pharmacol Sci 1991;12:260-264.
67. Janssen U, Walker S, Maier K, von Gaisberg U, Klotz U. Flumazenil disposition and elimination in cirrhosis. Clin Pharmacol Ther 1989;46:317-323.
68. Kapczinski F, Curran HV, Gray J, Lader M. Flumazenil has an anxiolytic effect in simulated stress. Psychopharmacology 1994;114:187-189.
69. Kaukinen S, Kataja J, Kaukinen L. Antagonism of benzodiazepine-fentanyl anesthesia with flumazenil. Can J Anaesth 1990;37:40-45.
70. Khan RM, Soliman MRI. Effects of benzodiazepine agonist, antagonist and inverse agonist on ethanol-induced changes in beta-endorphin levels in specific rat brain regions. Pharmacology 1993;47:337-343.
71. Klotz U. Drug interactions and clinical pharmacokinetics of flumazenil. Eur J Anaesthesiol (suppl 2) 1988;103-108.
72. Klotz U, Kanto J. Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). Clin Pharmacokinet 1988;14:1-12.
73. Kulka PJ, Lauven PM. Benzodiazepine antagonists. An update of their role in the emergency care of overdose patients. Drug Safety 1992;7:381-386.
74. Kumar BA, Forster MJ, Lal H. Senescence-like cognitive deficits in autoimmune NZB/BINJ mice are reversed by a benzodiazepine antagonist flumazenil. FASEB J 1988;2:A342.
75. Lader M, Morton S. A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal. J Psychopharmacol 1992;6:357-363.
76. Lal H, Kumar B, Forster MJ. Enhancement of learning and memory in mice by a benzodiazepine antagonist. FASEB J 1988;2:2707-2711.
77. A receptor subunit mRNAs in the rat brain. II. Olfactory bulb and cerebellum. J Neurosci 1992;12;1063-1076.
78. A receptor heterogeneity. Nature 1988;335:76-79.
79. Lheureux P, Askenasi R. Efficacy of flumazenil in acute alcohol intoxication: Double-blind placebo-controlled evaluation, Hum Exp Toxicol 1991;10:235-239.
80. Lheureux P, Vranckx M, Leduc D, Askenasi R. Risks of flumazenil in mixed benzodiazepine-tricyclic antidepressant overdose: Report of a preliminary study in the dog. J Toxicol Clin Exp 1992;12:43-53.
81. Lheureux P, Fontaine J, Askenasi R. Effect of flumazenil in a model of acute alcohol intoxication in rats. Hum Exp Toxicol 1993;12:177-180.
82. Linko K. Flumazenil (Ro 15-1788) in reversing diazepam sedation: A randomized clinical study. Eur J Anaesth (suppl 2) 1988:227-229.
83. Linowiecki K, Paloucek F, Donnelly A, Leikin JB. Reversal of ethanol induced respiratory depression by flumazenil. Vet Hum Toxicol 1992;34:417-419.
84. A receptor selective for a behavioral alcohol antagonist. Nature 1990;346:648-651.
85. A receptor subunits. Trends Pharmacol Sci 1991;12:49-51.
86. Luddens H, Seeburg PH, Korpi ER. Impact of β and γ variants on ligand-binding properties of gamma aminobutyric acid type A receptors. Mol Pharmacol 1994;45:810-814.
87. Luger TJ, Moravetz RF, Mitterschiffthaler G. Additional subcutaneous administration of flumazenil does not shorten recovery time after midazolam. Br J Anaesth 1990;64:53-58.
88. Lukas SE, Griffiths RR. Precipitated diazepam withdrawal in baboons: Effects of dose and duration of diazepam exposure. Eur J Pharmacol 1984;100:163-171.
89. A receptor channels. Annu Rev Neurosci 1994;17:569-602.
90. Maddison JE, Dodd PR, Johnson OAR, Farrel GC. Brain gamma aminobutyric acid receptor binding is normal in rats with thioacetamide-induced hepatic encephalopathy despite elevated plasma gamma aminobutyric acid like activity. Gastroenterology 1987;93:1062-1068.
91. Malizia AL, Nutt DJ. The effects of flumazenil in neuropsychiatric disorders. Clin Neuropharmacol 1995;18:215-232.
92. Mandema JW, Gubbens-Stibbe JM, Danhof M. Stability and pharmacokinetics of flumazenil in the rat. Psychopharmacology 1991;103:384-387.
93. Mandema JW, Tukker E, Danhof M. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: Midazolam and flumazenil. J Pharmacol Exp Ther 1992;260:36-44.
94. Mans AM, Kukulka KM, McAvoy KJ, Rokozs NC. Regional distribution and kinetics of three sites on the GABA-A receptor: Lack of effect of portocaval shunting. J Cereb Blood Flow Metab 1992;12:334-346.
95. Marczynski TJ, Artwohl J, Marczynska B. Chronic administration of flumazenil increases life span and protects rats from age-related loss of cognitive functions: A benzodiazepine/GABAergic hypothesis of brain aging. Neurobiol Aging 1994;15:69-84.
96. Massarella J, Schwam E, Pitman V, Choma N, Brown S. Food increases the clearance of flumazenil during intravenous infusion. Clin Pharmacol Ther 1990;47:182.
97. Meier R, Gyr K. Treatment of hepatic encephalopathy with the benzodiazepine antagonist flumazenil: A pilot study. Eur J Anaesthesiol (suppl 2) 1988:139-146.
98. Mohler H, Battersby MK, Richards JG. Benzodiazepine receptor protein identified and visualized in brain tissue by a photoaffinity label. Proc Natl Acad Sci USA 1980;77:1666-1670.
99. A receptors by cAMP-dependent protein phosphorylation. Science 1992;257:661-665.
100. A receptor determined by electron microscope image analysis. J Neurochem 1994;62:815-818.
101. Nutt DJ, Cowen PJ, Little HJ. Unusual interactions of benzodiazepine receptor antagonists. Nature 1982;295:436-438.
102. Nutt DJ, Costello MJ. Rapid induction of lorazepam dependence and reversal with flumazenil. Life Sci 1988;43:1045-1053.
103. Nutt DJ, Glue P, Lawson C, Wilson S. Evidence for altered benzodiazepine receptor sensitivity in panic disorder: Effects of the benzodiazepine receptor antagonist flumazenil. Arch Gen Psychiatry 1990;47:917-925.
104. Nutt DJ, Wilson S, Eames P. Does the benzodiazepine receptor have a role in epilepsy? In: Rose C, ed. Advances in Neuropharmacology. London: Smith-Gordon, 1993:107-112.
105. Nutt DJ, Coupland N, Malizia A, Bailey J. Benzodiazepine receptors in alcohol withdrawal. Neuropsychopharmacotogy 1994;10:85S.
106. A receptors. FASEB J 1990;4:1469-1480.
107. Olsen RW, Sapp DM, Bureau MH, Turner DM, Kokka N. Allosteric actions of central nervous system depressants including anesthetics on subtypes of the inhibitory gamma aminobutyric acid A receptor-chloride channel complex. Ann NY Acad Sci 1991;625: 145-154.
108. Olsen RW, Venter JC. Benzodiazepine/GABA Receptors and Chloride Channels: Structural and Functional Properties. Receptor Biochemistry and Methodology. Vol. 5, New York: Allan R. Liss, 1986.
109. Patat A, Naef MM, Van Gessel E, Forster A, Dubruc C, Rosenzweig P. Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic. Clin Pharmacol Ther 1994;56:430-436.
110. 14C]-labelled Ro 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. J Psychiatr Res 1985;19:609-622.
111. Polc P, Laurent JP, Scherschlicht R, Haefely W. Electrophysiological studies on the specific benzodiazepine antagonist Ro 15-1788. Naunyn-Schmiedeberg's Arch Pharmacol 1981;316:317-325.
112. Pomier-Layrargues G, Giguere JF, Lavoie J, et al. Flumazenil in cirrhotic patients in hepatic coma: A randomised double blind placebo controlled crossover trial. Hepatology 1994;19:32-37.
113. A benzodiazepine receptors produced in transfected cells. Science 1989;245:1389-1392.
114. A receptor subunit for benzodiazepine pharmacology. Nature 1989;338:582-585.
115. 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem 1990;54:1802-1804.
116. Pritchett DB, Seeburg PH. γ-Aminobutyric acid type A receptor point mutation increases the affinity of compounds for the benzodiazepine site. Proc Natl Acad Sci USA 1991;88:1421-1425.
117. Püspök A, Herneth A, Steindl P, Ferenci P. Hepatic encephalopathy in rats with thioacetamide-induced acute liver failure is not mediated by endogenous benzodiazepines. Gastroenterology 1993;105:851-857.
118. Reisner-Keller LA, Pham Z. Oral flumazenil in the treatment of epilepsy. Ann Pharmacol Ther 1995;29:530-531.
119. Roncari G, Ziegler WH, Guentert TW. Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration. Br J Clin Pharmacol 1986;22:421-428.
120. Samson Y, Bemann J, Pappata S, et al. Cerebral uptake of benzodiazepines measured by positron emission tomography in hepatic encephalopathy. N Engl J Med 1987;316:414-415.
121. Sandler M. The emergence of tribulin. Trends Pharmacol Sci 1982;3:471-472.
122. Savic I, Widen L, Stone-Elander S. Feasibility of reversing benzodiazepine tolerance with flumazenil. Lancet 1991;337:133-137.
123. Schafer DF, Fowler JM, Munson PJ, Thabur AK, Waggoner JG, Jones EA. GABA and benzodiazepine receptors in an animal model of fulminant hepatic failure. J Lab Clin Med 1983;102:870-880.
124. Schofield PR, Darlison MG, Fujita N, et al. Sequence and functional expression of the GABA-A receptor shows ligand-gated receptor superfamily. Nature 1987;328:221-223.
125. Scollo-Lavizzari, Steinman XX. Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-1788). Lancet 1985;i:1324.
126. Seifritz E, Hemmeter U, Trachsel L, et al. Effects of flumazenil on recovery sleep and hormonal secretion after sleep deprivations in male controls. Psychopharmacol 1995;120:449-456.
127. Sharief MK, Sander JW, Shorvon SD. The effect of oral flumazenil on interictal epileptic activity: Results of a double-blind placebo-controlled study. Epilepsy Res 1993;15:53-60.
128. 1 receptor RNA induces bicuculline-, barbiturate-, and benzodiazepine-insensitive γ-aminobutyric acid responses in Xenopus oocytes. Mol Pharmacol 1991;41:683-687.
129. A receptor subunits exist in distinct neuronal subpopulations. Neuron 1989;3:327-337.
130. Short KR, Maier SF. Localisation of a benzodiazepine receptor-mediated control dependent increase in anxiety following stress in the rat. Soc Neurosci Abstr 1991;16:338.
131. A receptor subtypes. Pharmacol Rev 1995;47:181-234.
132. Sierralta F, Miranda HF. Analgesic effect of benzodiazepines and flumazenil. Gen Pharmac 1992;23:739-742.
133. Sigel E. Barnard EA. A gamma-aminobutyric acid/benzodiazepine receptor complex from bovine cerebral cortex. Improved purification with preservation of regulatory sites and their interactions. J Biol Chem 1984;259:7219-7223.
134. Spivey WH. Flumazenil and seizures. Analysis of 43 cases. Clin Ther 1992;14:292-305.
135. Sprengel R, Werner P, Seeburg PH, et al. Molecular cloning and expression of cDNA encoding a peripheral-type benzodiazepine receptor. J Biol Chem 1989;264:20415-20421.
136. Steinhoff BJ, Stodieck SR. Temporary abolition of seizure activity by flumazenil in a case of valproate-induced non-convulsive status epilepticus. Seizure 1993;2:261-265.
137. A-receptor function in hippocampal cells is maintained by phosphorylation factors. Science 1988;241:339-341.
138. Stuhmer W. Structure and function of sodium channels. Cell Physiol Biochem 1993;3:277-282.
139. Sugarman JM, Paul RI. Flumazenil: A review. Pediatr Emerg Care 1994;10:37-43.
140. Tang M, Soroka S, Falk JL. Agonistic action of a benzodiazepine antagonist: Effects of Ro 15-1788 and midazolam on hypertonic NaCl intake. Pharmacol Biochem Behav 1983;18:953-955.
141. The flumazenil in benzodiazepine intoxication multicenter study group. Treatment of benzodiazepine overdose with flumazenil. Clin Ther 1992;14:978-995.
142. Thiébot MH, Childs M, Soubrié P, Simon P. Diazepam-induced release of behaviour in an extinction procedure: Its reversal by Ro 15-1788. Eur J Pharmacol 1983;88:111-116.
143. Van der Rijt CCD, de Knegt RJ, Schalm SW, Terpstra OT, Mechelse K. Flumazenil does not improve hepatic encephalopathy associated with acute ischemic liver failure in the rabbit. Metab Brain Dis 1990;5:131-141.
144. Velluci SV, Webster RA. Antagonism of the anticonflict effects of chlordiazepoxide by beta-carboline carboxylic acid ethyl ester, Ro 15-1788, and ACTH (4-10). Psychopharmacology 1982;78:256-260.
145. Wafford KA, Burnett DM, Leidenheimer NJ, et al. Ethanol sensitivity of the GABA-A receptor expressed in Xenoptis oocytes requires 8 amino acids contained in the gamma-2L subunit. Neuron 1991;7:27-33.
146. Walla EP, Sloan JW. Flumazenil, diazepam, nordiazepam, and oxazepam interactions on plasma protein binding. Pharmacol Res 1995;32:299-304.
147. Weinbroum A, Halpern P, Geller E. The use of flumazenil in the management of acute drug poisoning - a review. Intensive Care Med 1991;17:532-538.
148. Wesensten NJ, Balkin TJ, Davis HQ, Belenky GL. Reversal of triazolam- and zolpidem-induced memory impairment by flumazenil. Psychopharmacology 1995;121:242-249.
149. A receptors is essential for benzodiazepine agonist binding. J Biol Chem 1992;267:1426-1429.
150. 4-subunit. FEBS Lett 1991;289:227-230.
151. A receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci 1992;12:1040-1062.
152. Woods SW, Charney DS, Silver JM, Krystal JH, Heninger GR. Behavioural and biochemical and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Res 1991;36:115-127.
153. A/benzodiazepine receptors. EMBO J 1990;9:3261-3267.
154. Zhi J, Massarella JW, Melia AT, et al. The pharmacokinetic-pharmacodynamic (digit symbol substitution test) relationship of flumazenil in a midazolam steady-state model in healthy volunteers. Clin Pharmacol Ther 1994;56:530-536.